Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Opus Group in conjunction with issuance of bonds
Mandate

Vinge advises Opus Group in conjunction with issuance of bonds

May 28, 2018 Capital Markets and Public M&A

Opus Group AB (publ) (”Opus”) has issued a so called senior unsecured bond in the amount of MSEK 500 MSEK with a term of four years on the Nordic market.

The bond, with a framework amount of MSEK 800, is subject to a variable interest rate of STIBOR 3m + 375 interest points and has a final maturity date in May 2022. The proceeds from the bond issue will primarily be used for refinancing Opus’ outstanding bond in the amount of MSEK 500 with a final maturity date on 20 November 2018 (ISIN: SE0005556834). Opus will apply for listing of the bond on Nasdaq Stockholm.

Vinge’s team consisted of partner Anders Strid together with, among others, associates Yohanna Öhrnegård and Lina André.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024